Immunotherapy Breakthroughs for Esophageal Cancer Patients
The early results of two large, Phase III clinical trials of the immunotherapy Opdivo (nivolumab) showed significant survival benefits for [...]
Barrett’s Esophagus and Esophageal Adenocarcinoma can run in Families
The familial connection is one of the Strongest Indicators of Risk according to Experts. ECAN spoke with the Leading Researcher [...]
FDA calls New Screening Test Using DNA to Detect Esophageal Cancer a Breakthrough Device
First Time the FDA has given Breakthrough Designation for a Device Targeting Diseases of the Esophagus. Lucid Diagnostics' EsoGuard™ Esophageal [...]
FDA Approves First Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma
The U.S. Food and Drug Administration has approved Keytruda (Pembrolizumab) for treatment of advanced Esophageal Squamous Cell Carcinoma (ESCC). It [...]
First Patient Dosed in Phase 3 Trial Testing Tyvyt as First-line Therapy for Esophageal Cancer
First Esophageal Cancer patient is dosed in Phase 3 clinical trial using immune checkpoint inhibitor Tyvyt (sintilimab injection), in [...]
$26 Million ‘Grand Challenge’ Project Will Probe Role of Inflammation in Cancer
Unprecedented International Collaboration will Focus on Esophageal and other Cancers with $26 Million UK Grant. Read more about this [...]
Newly Diagnosed Cancer Patients who have Hepatitis are Unaware of the Hepatitis Status
Study Finds Many Newly Diagnosed Cancer Patients who have Hepatitis are Unaware of the Hepatitis Status - Prompting a [...]
Esophageal Cancer Genome
ECAN’s President and CEO Mindy Mintz Mordecai recently had the opportunity to interview Dr. Adam Bass, co-chair of the [...]